 BELTSVILLE, Md., Nov. 05, 2020 GLOBE NEWSWIRE -- NextCure, Inc. Nasdaq: NXTC, a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2020 financial results and provided a business update. 